Related Experiment Video
Updated: Jun 8, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus
Alejandra Larrieux1, Rafael Sanjuán2
1Institute for Integrative Systems Biology (I2SysBio), Universitat de València-CSIC, Paterna, 46980, València, Spain.
Abstract:
Oncolytic virotherapy has shown efficacy in various animal models and a few human cancers. However, there are still significant limitations for the implementation of these therapies. One such limitation is the emergence of cellular resistances, which may appear rapidly considering the high genetic heterogeneity of most tumors. We previously showed that cellular resistance to an oncolytic virus can be mediated by the chronic activation of innate immunity. Here, we explored the existence of additional resistance mechanisms in murine colon cancer-derived cells. For this purpose, we isolated two cellular clones that were resistant to the oncolytic virus VSV-D51. While one of the clones showed a strong resistance profile associated with increased cytokine-mediated antiviral responses, the other clone showed a lower level of resistance that involves cytoskeletal reorganization, signaling by small GTPases, and cell structural changes. These results demonstrate the capacity of tumor cells to deploy heterogeneous mechanisms of resistance to oncolytic viruses.
Insights
Tumor cells can rapidly develop resistance to oncolytic viruses, a promising cancer therapy. This study identified two distinct resistance mechanisms in colon cancer cells, highlighting the challenge of viral oncology treatments.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Immunology
Background:
- Oncolytic virotherapy utilizes viruses to selectively infect and destroy cancer cells, showing promise in preclinical and clinical settings.
- A significant challenge to oncolytic virotherapy is the rapid emergence of cellular resistance, driven by tumor heterogeneity.
- Previous research indicated that chronic activation of innate immunity can mediate resistance to oncolytic viruses.
Purpose of the Study:
- To investigate additional resistance mechanisms beyond innate immunity in murine colon cancer cells against oncolytic viruses.
- To characterize the distinct cellular adaptations that confer resistance to the oncolytic virus VSV-D51.
Main Methods:
- Isolation and characterization of two distinct cellular clones resistant to VSV-D51 from murine colon cancer cell lines.
- Analysis of antiviral responses, cytokine production, and cellular signaling pathways in resistant clones.
- Investigation of cytoskeletal dynamics and cell structural changes associated with resistance.
Main Results:
- One resistant clone exhibited strong resistance linked to enhanced cytokine-mediated antiviral responses.
- A second resistant clone displayed lower-level resistance involving significant cytoskeletal reorganization and alterations in small GTPase signaling.
- These findings reveal diverse cellular strategies employed by tumor cells to evade oncolytic virus therapy.
Conclusions:
- Tumor cells can develop heterogeneous mechanisms of resistance to oncolytic viruses, complicating treatment efficacy.
- Understanding these diverse resistance pathways is crucial for developing more effective and durable oncolytic virotherapy strategies.
- Targeting both immune-mediated and structural resistance mechanisms may be necessary to overcome treatment limitations.
